Enliven Therapeutics (ELVN) Depreciation and Depletion (2019 - 2026)

Enliven Therapeutics has disclosed Depreciation and Depletion across 8 years of filings, most recently posting $14000.0 for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $14000.0, down 81.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $203000.0 (down 34.94% YoY), and the FY2025 annual result was $263000.0, down 17.03% from the prior year.
• Depreciation and Depletion came in at $14000.0 for Q1 2026 at Enliven Therapeutics, down from $46000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $400000.0 in Q2 2022 to a low of $14000.0 in Q1 2026.
• The 5-year median for Depreciation and Depletion is $74000.0 (2023), against an average of $85529.4.
• Across the five-year window, Depreciation and Depletion jumped 1500.0% in 2022 and plunged 81.5% in 2023, its largest moves.
• Enliven Therapeutics' Depreciation and Depletion stood at $64000.0 in 2022, then gained by 21.88% to $78000.0 in 2023, then gained by 2.56% to $80000.0 in 2024, then sank by 42.5% to $46000.0 in 2025, then tumbled by 69.57% to $14000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $14000.0 (Q1 2026), $46000.0 (Q4 2025), and $62000.0 (Q3 2025), per Business Quant data.